Salmeterol response is not affected by beta2 -adrenergic receptor genotype in patients with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 505s Year: 2005
The role of glucocorticoid receptor a and ß isoforms in exacerbations of asthma, COPD, and ACOS Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017
G-protein coupled receptor gene polymorphism is associated with asthma and asthma severity in Russian patients Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases Year: 2008
Predictors for asthma onset from cough variant asthma Source: Eur Respir J 2002; 20: Suppl. 38, 409s Year: 2002
COPD patients with asthma, characteristics and risk of exacerbations Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
A polymorphism in DNASE1L3 is associated with severe asthma exacerbations in two-high risk populations for asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019
Genetic comparison between severe persistent asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 81s Year: 2003
Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007
Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Maximal airway response in patients with asthma and cough variant asthma Source: Annual Congress 2007 - COPD, sarcoidosis, idiopathic pulmonary fibrosis, cystic fibrosis, gastro-oesophageal reflux and cough variant asthma - pathogenesis and differential diagnosis Year: 2007
The median number of COPD exacerbations per year in patients with different polymorphisms of the gene ADRB2 Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020
Factors associated with frequent exacerbations in patients with severe asthma Source: Eur Respir J 2001; 18: Suppl. 33, 369s Year: 2001
Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013